- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07223203
TRITON-PN: En studie for å evaluere effektiviteten og sikkerheten til Nucresiran hos pasienter med arvelig transtyretyn-amyloidose med polynevropati (TRITON-PN)
TRITON-PN: En fase 3, global, randomisert, åpen studie for å evaluere effektiviteten og sikkerheten til Nucresiran hos pasienter med arvelig transtyreitin-mediert amyloidose med polynevropati (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trial Information Line
- Telefonnummer: 1-877-ALNYLAM
- E-post: clinicaltrials@alnylam.com
Studer Kontakt Backup
- Navn: Clinical Trial Information Line
- Telefonnummer: 1-877-256-9526
- E-post: clinicaltrials@alnylam.com
Studiesteder
-
-
-
Belgrano, Argentina, C1428AQK
- Rekruttering
- Clinical Trial Site
-
Rosario, Argentina, CP2000
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australia, 2010
- Rekruttering
- Clinical Trial Site
-
Woolloongabba, Australia, 4102
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brasil, 14051-140
- Rekruttering
- Clinical Trial Site
-
Rio de Janeiro, Brasil, 22640-100
- Rekruttering
- Clinical Trial Site
-
Rio de Janeiro, Brasil, 22775-001
- Rekruttering
- Clinical Trial Site
-
Salvador, Brasil, 40290-000
- Rekruttering
- Clinical Trial Site
-
São Paulo, Brasil, 04038-002
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canada, V5Z 1M9
- Rekruttering
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02118
- Rekruttering
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Clinical Trial Site
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Clinical Trial Site
-
New York, New York, Forente stater, 10016
- Rekruttering
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Clinical Trial Site
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Créteil, Frankrike, 94000
- Rekruttering
- Clinical Trial Site
-
Le Kremlin-Bicêtre, Frankrike, 94270
- Rekruttering
- Clinical Trial Site
-
Marseille, Frankrike, 13005
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Athens, Hellas, 115 28
- Rekruttering
- Clinical Trial Site
-
Heraklion, Hellas, 715 00
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Dublin, Irland, D24 NR0A
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Florence, Italia, 50134
- Rekruttering
- Clinical Trial Site
-
Milan, Italia, 20133
- Rekruttering
- Clinical Trial Site
-
Padova, Italia, 35128
- Rekruttering
- Clinical Trial Site
-
Pavia, Italia, 27100
- Rekruttering
- Clinical Trial Site
-
Roma, Italia, 00168
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Japan, 113-8519
- Rekruttering
- Clinical Trial Site
-
Kumamoto, Japan, 860-8556
- Rekruttering
- Clinical Trial Site
-
Matsumoto-shi, Japan, 390-8621
- Rekruttering
- Clinical Trial Site
-
Suita, Japan, 565-0871
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Égkomi, Kypros, 2371
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Guadalajara, Mexico, 44670
- Rekruttering
- Clinical Trial Site
-
Tlalpan, Mexico, 14080
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Rekruttering
- Clinical Trial Site
-
Porto, Portugal, 4099-001
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Clinical Trial Site
-
Huelva, Spania, 21005
- Rekruttering
- Clinical Trial Site
-
L'Hospitalet de Llobregat, Spania, 8907
- Rekruttering
- Clinical Trial Site
-
Madrid, Spania, 28040
- Rekruttering
- Clinical Trial Site
-
Palma de Mallorca, Spania, 07198
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
London, Storbritannia, NW3 2QG
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Bern, Sveits, 3010
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Stockholm, Sverige, 113 61
- Rekruttering
- Clinical Trial Site
-
Umeå, Sverige, 907 37
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Clinical Trial Site
-
Seoul, Sør -Korea, 05030
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Rekruttering
- Clinical Trial Site
-
Taipei, Taiwan, 112
- Rekruttering
- Clinical Trial Site
-
Taoyuan City, Taiwan, 33305
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Istanbul, Tyrkia (Türkiye), 34093
- Rekruttering
- Clinical Trial Site
-
Izmir, Tyrkia (Türkiye), 35330
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Clinical Trial Site
-
Heidelberg, Tyskland, 69120
- Rekruttering
- Clinical Trial Site
-
Münster, Tyskland, 48149
- Rekruttering
- Clinical Trial Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andre navn:
|
|
Aktiv komparator: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andre navn:
Vutrisiran 25 mg administered SC q3M
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prosentvis reduksjon i serum TTR-nivå i nukresiran-gruppen sammenlignet med vutrisiran-gruppen i studien gjennom måned 9
Tidsramme: Opp til måned 9
|
Opp til måned 9
|
|
|
Prosentvis reduksjon i serum TTR-nivåer i nukresiran-gruppen sammenlignet med vutrisiran-gruppen i studien gjennom måned 18
Tidsramme: Opptil måned 18
|
Opptil måned 18
|
|
|
Prosentvis reduksjon i serum TTR-nivåer i Nucresiran-gruppen sammenlignet med Vutrisiran-gruppen i studien ved uke 6
Tidsramme: Uke 6
|
Uke 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Medical Director, Alnylam Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .